Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 21 December 2011
The US Food and Drug Administration (FDA) issued an interim final rule last week that clarifies what a 'discontinuance' of production of a drug is and what 'sole manufacturer' means when it comes to a pharmaceutical company's duty to inform federal officials about a potential shortage. The new regulation defines a 'discontinuance' as either a permanent or temporary disruption in the supply of a product. Previously, companies had to inform FDA only when they permanently stopped making a particular medicine. The initiative would increase visibility about shortages between industry and the FDA, according to the trade group. It would also require acceptance by the Federal Trade Commission and Health and Human Services. (California Healthline)
Tags: sole manufacturer, manufacturer, production, discontinue, discontinuance, interim final rule